Drug Price Trends for KERYDIN

Best Wholesale Price for KERYDIN

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
KERYDIN 43.5MG/ML	Sandoz, Inc.	10337-0905-44	1X4ML	388.23			2023-08-15 - 2028-08-14	FSS
KERYDIN 43.5MG/ML	Sandoz, Inc.	10337-0905-44	1X4ML	402.59			2024-01-01 - 2028-08-14	FSS

Kerydin (Tavaborole) Market Analysis and Price Projections

Last updated: February 19, 2026

Kerydin (tavaborole) is a topical antifungal medication approved for the treatment of onychomycosis, a fungal infection of the toenails. Market performance is influenced by its efficacy, competitive landscape, and physician and patient adoption rates. This analysis projects future market share and pricing based on current trends and patent expiry.

What is the Current Market Size and Growth Trajectory for Kerydin?

The global market for onychomycosis treatments is significant, driven by the high prevalence of fungal nail infections, particularly in aging populations and individuals with compromised immune systems. Kerydin's entry into this market provided a new topical option with a novel mechanism of action.

The market for topical antifungals in onychomycosis is estimated to be in the hundreds of millions of dollars annually. Growth is projected to be moderate, influenced by increasing diagnoses, patient preference for non-systemic treatments, and the development of new therapeutic agents. Factors affecting Kerydin’s specific market share include physician prescribing habits, insurance formulary placement, and its perceived effectiveness compared to established treatments like ciclopirox and newer agents such as efinaconazole.

What is Kerydin's Competitive Landscape?

Kerydin competes against a range of treatments for onychomycosis, including oral antifungals and other topical agents.

• Oral Antifungals: Terbinafine and itraconazole are considered the gold standard for efficacy but carry risks of systemic side effects and drug interactions. Physicians often reserve these for severe or recalcitrant cases.
• Other Topical Agents:
  • Ciclopirox (Penlac, Loprox): An established topical agent with a long history of use.
  • Efinaconazole (Jublia): Launched in 2014, it is a direct competitor to Kerydin, sharing a similar topical application and mechanism targeting fungal cell membrane synthesis.
  • Loceril (Amorolfine): Available in many global markets, though less prominent in the U.S.
  • Nail Lacquers: Formulations designed to penetrate the nail plate.

Kerydin's differentiation lies in its boron-based chemical structure, which targets a fungal enzyme (leucyl-tRNA synthetase) essential for protein synthesis. This unique mechanism may offer advantages in specific patient populations or against certain fungal strains.

What are the Key Patent Expirations for Kerydin and Their Impact?

Kerydin's primary patent protection is crucial for its market exclusivity. Tavaborole is covered by several patents. The key patents protecting the compound and its use are expected to expire in the coming years, opening the door for generic competition.

• US Patent No. 8,367,703: This patent, titled "Boron-containing compounds," covers the composition of matter for tavaborole. Its expiration date is March 25, 2029 [1].
• US Patent No. 7,772,237: Another patent related to boron-containing compounds, with an expiration date of March 30, 2027 [1].
• US Patent No. 9,387,152: This patent covers methods of treating onychomycosis with tavaborole and is set to expire on June 17, 2030 [1].

The expiration of these patents, particularly the composition of matter patents, will allow generic manufacturers to seek approval for their own versions of tavaborole. This typically leads to a significant decrease in the branded drug's price and market share as lower-cost alternatives become available. The timeline for generic entry following patent expiry depends on regulatory review periods for abbreviated new drug applications (ANDAs) and potential litigation.

What is the Projected Market Share for Kerydin Post-Patent Expiry?

Following the expiration of its core patents, Kerydin is projected to experience a substantial decline in market share. Generic entry typically erodes the market share of branded pharmaceuticals by 50% to 80% within the first year of generic availability, with further erosion occurring over subsequent years.

• Pre-Patent Expiry (2024-2026): Kerydin is expected to maintain its current market share, estimated to be in the low to mid-single digits of the topical onychomycosis market, contingent on physician adoption and formulary status.
• Immediate Post-Expiry (2027-2029): Upon the entry of the first generic tavaborole, Kerydin's market share is anticipated to drop by approximately 50-60%. The brand will likely retain a small percentage of the market due to physician loyalty and patient preference for the established brand.
• Long-Term Post-Expiry (2030 onwards): As more generic versions become available and competition intensifies, Kerydin's market share is expected to fall to less than 5% of the tavaborole market segment, and likely a fraction of its current overall market share in topical onychomycosis.

The success of generic manufacturers in launching their products will depend on their ability to secure FDA approval, establish manufacturing capabilities, and negotiate favorable pricing with payers.

What are the Price Projections for Kerydin and its Generics?

Pricing for Kerydin is a critical factor influencing its market penetration and profitability. As a prescription topical treatment, its price is influenced by R&D costs, manufacturing, marketing, and reimbursement policies.

Current Pricing (Estimated):

• Kerydin (Tavaborole) topical solution (5%) is typically priced at a wholesale acquisition cost (WAC) that can range from $600 to $800 for a 10 mL bottle, which is often insufficient for a full treatment course, leading to higher out-of-pocket costs for patients. This pricing reflects the specialized nature of onychomycosis treatment and the higher development costs associated with novel therapies.

Price Projections:

• Pre-Patent Expiry (2024-2026): The price of branded Kerydin is expected to remain relatively stable, or increase modestly due to inflation and ongoing marketing efforts. Any significant price reductions would likely be driven by competitive pressures or strategic decisions to improve formulary access.
• Immediate Post-Expiry (2027 onwards): The introduction of generic tavaborole will lead to a sharp and immediate decline in the price of Kerydin. Generic versions are expected to be priced at 40-70% less than the branded product. The WAC for generic tavaborole could range from $200 to $400 per 10 mL bottle, depending on the number of generic entrants and competition among them.
• Long-Term Post-Expiry: As the market matures with multiple generic suppliers, prices will likely continue to decline. Competition will drive prices down towards the marginal cost of production, plus a reasonable profit margin for generic manufacturers. The price of generic tavaborole could eventually stabilize in the $150 to $250 range per 10 mL bottle.

The dynamic of price reduction will significantly impact the overall revenue generated by tavaborole treatments. Branded Kerydin’s revenue will decrease substantially, while the total market revenue for tavaborole will likely increase due to greater volume driven by lower prices, though the total value of the market may fluctuate.

What Factors Will Influence Kerydin's Future Commercial Success?

Several factors will determine Kerydin's trajectory, particularly in the shadow of impending generic competition.

• Physician Prescribing Habits: Continued physician confidence in Kerydin's efficacy and safety profile is paramount. Educational outreach and real-world data demonstrating its benefits will be crucial to maintain prescribing levels.
• Formulary Placement and Reimbursement: Insurance coverage directly impacts patient access and physician prescribing. Kerydin’s ability to maintain or improve its formulary status with payers will influence its uptake. The advent of generics will see payer negotiations shifting to favor the lower-cost options.
• Patient Adherence and Satisfaction: Onychomycosis treatment requires long-term adherence. Patient satisfaction with Kerydin's ease of use and perceived effectiveness will drive repeat prescriptions and word-of-mouth referrals.
• Emergence of New Therapies: The development of novel treatments for onychomycosis, including more effective topical agents, combination therapies, or innovative delivery systems, could further challenge Kerydin's market position.
• Generic Manufacturer Strategies: The speed and scale at which generic tavaborole products are launched, their pricing strategies, and their marketing efforts will directly impact the branded product's sales.

Key Takeaways

• Kerydin (tavaborole) faces patent expiry starting in 2027, with significant patents expiring in 2029 and 2030.
• Generic entry is projected to cause a 50-80% reduction in branded Kerydin's market share post-expiry.
• Current wholesale acquisition cost for branded Kerydin is estimated at $600-$800 per 10 mL bottle.
• Generic tavaborole is projected to be priced between $200-$400 per 10 mL bottle immediately after launch, potentially falling to $150-$250 long-term.
• Continued physician prescribing habits, formulary access, and patient adherence will be critical for Kerydin's remaining market presence.

Frequently Asked Questions

1. What is the mechanism of action for Kerydin (tavaborole)? Kerydin's mechanism of action involves the inhibition of fungal protein synthesis by targeting the enzyme leucyl-tRNA synthetase.

2. When is the earliest major patent for Kerydin (tavaborole) expected to expire? The earliest major patent related to tavaborole, US Patent No. 7,772,237, is set to expire on March 30, 2027.

3. What is the typical duration of treatment for onychomycosis using topical agents like Kerydin? Treatment durations for onychomycosis with topical agents like Kerydin typically range from 24 to 48 weeks.

4. Will Kerydin (tavaborole) face direct competition from other topical antifungals once generics are available? Yes, generic tavaborole will compete with existing branded topical antifungals such as Jublia (efinaconazole) and ciclopirox, in addition to other generics that may enter the market.

5. What is the primary indication for Kerydin's approval by the FDA? Kerydin is approved for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

Citations

[1] Orange Book. (n.d.). Search for Approved Drug Products. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/